Sale!

Del13q MM CLL Test Cost

Original price was: 1,400 د.إ.Current price is: 1,050 د.إ.

-25%

The Del13q MM CLL Test is a specialized genetic test performed at DNA Labs UAE, aimed at detecting the deletion of chromosome 13q, which is a common genetic abnormality associated with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). This test is crucial for the diagnosis, prognosis, and management of patients with these hematological malignancies. By identifying the deletion of chromosome 13q, healthcare providers can better understand the disease’s behavior, predict treatment responses, and tailor therapeutic strategies accordingly.

The test is conducted using advanced molecular techniques to analyze the patient’s DNA for the specific deletion. It is a valuable tool in the personalized medicine approach, helping in stratifying patients according to their genetic risk and guiding decision-making regarding their treatment.

The cost of the Del13q MM CLL Test at DNA Labs UAE is set at 1050 AED. This price reflects the comprehensive nature of the test, including the sophisticated laboratory analysis and the expertise required to accurately interpret the results. Patients seeking this test can expect a reliable service that contributes significantly to the effective management of multiple myeloma and chronic lymphocytic leukemia.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Del13q MM CLL Test

Components: Sodium Heparin Vacutainer (2ml)

Price: 1050.0 AED

Sample Condition: Bone Marrow / Peripheral blood

Report Delivery: 3-4 days

Method: FISH

Test type: Genetics

Doctor: Oncology

Test Department:

Pre Test Information: Del 13q (MM, CLL) can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

Del[13q] refers to a genetic abnormality found in certain types of cancer, specifically in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). It is characterized by a deletion of the long arm of chromosome 13 (q arm). This deletion is associated with a poorer prognosis and may affect the response to treatment.

In multiple myeloma, Del[13q] is one of the most common chromosomal abnormalities and is often associated with other genetic abnormalities. It has been linked to more aggressive disease progression and a shorter overall survival rate.

In chronic lymphocytic leukemia, Del[13q] is also a common genetic abnormality, occurring in approximately 50% of cases. It is associated with a more favorable prognosis compared to other genetic abnormalities commonly found in CLL.

The presence of Del[13q] is often detected through genetic testing, such as fluorescence in situ hybridization (FISH), which can identify specific chromosomal abnormalities. This information is important in determining the appropriate treatment approach and predicting the patient’s response to therapy.

Test Name Del13q MM CLL Test
Components Sodium Heparin Vacutainer (2ml)
Price 1050.0 AED
Sample Condition Bone Marrow \/ Peripheral blood
Report Delivery 3-4 days
Method FISH
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information Del 13q] (MM, CLL) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

Del[13q] refers to a genetic abnormality found in certain types of cancer, specifically in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). It is characterized by a deletion of the long arm of chromosome 13 (q arm). This deletion is associated with a poorer prognosis and may affect the response to treatment.

In multiple myeloma, Del[13q] is one of the most common chromosomal abnormalities and is often associated with other genetic abnormalities. It has been linked to more aggressive disease progression and a shorter overall survival rate.

In chronic lymphocytic leukemia, Del[13q] is also a common genetic abnormality, occurring in approximately 50% of cases. It is associated with a more favorable prognosis compared to other genetic abnormalities commonly found in CLL.

The presence of Del[13q] is often detected through genetic testing, such as fluorescence in situ hybridization (FISH), which can identify specific chromosomal abnormalities. This information is important in determining the appropriate treatment approach and predicting the patient’s response to therapy.